CJC-1295 DAC Peptide (5MG)
This batch of CJC-1295 DAC has been third party lab tested and verified for quality.
TESTED FOR:
purity
weight
endotoxins(lps)
$41.99
| Discount | Quantity | Price |
|---|---|---|
| 0% | 1 - 4 | $41.99 |
| 10% Off | 5 - 9 | $37.79 |
| 15% Off | 10 - 24 | $35.69 |
| 25% Off | 25 + | $31.49 |
This product is in powder form and is not reconstituted.
All products and materials sold on this site are not for human consumption and subject to our Terms and Conditions.
SHIPS TODAY
Order by 1:00 PM EST
FREE SHIPPING
For orders over $200
ICE PACK SHIPPING
Styrofoam box shipping available
Bottle: vial - sealed - flip top
Vial size: 3ml
Form: powder (lyophilized)
Not reconstituted
| CJC-1295 DAC Test Results | Results | |
|---|---|---|
CJC1295 DAC Test results | ||
Date Tested: | September 20, 2025 | |
Purity: | 99.366% | |
Weight: | 4.91mg | |
Endotoxins (LPS): | Pass | |
Batch #: | 10-25-0805G | |
CJC-1295 DAC Peptide Information
FORM |
Powder(lyophilized) |
|---|---|
CAS NUMBER |
446262-90-4 |
OTHER NAMES |
CJC1295, CJC-1295 with DAC, |
WEIGHT |
5mg |
SEQUENCE |
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 |
Molecular Weight |
3647.15 g/mol |
Terms |
Subject to our Terms and Conditions. This material is sold for laboratory research use only. Not for human consumption, animal, or medical use. |
Why isn’t there more information on CJC-1295 DAC peptides?
Due to the legal landscape of peptides and research products, providing information that may imply anything beyond laboratory research use is a legal liability. We’re an expert biotechnology company that provides high quality peptides and products for purchase to advance scientific research in this field.
Why Choose Verified Peptides?
The industry's most trusted source for research peptides
The #1 Leader In Peptide Testing
300+ Certificates of Analysis
What does this mean for you? You can be sure we don't cut corners on testing every single batch.
Visit our Lab Reports page.
A Long Standing Trusted Company
5+ Years of Peptides
We pioneered third party lab testing and have stood the test of time. Our first lab report dates back to 2019 proving our track record.
The Highest Quality at the Best Prices
You won't find this degree of testing and quality at this price.
Peptides Tested For More Than Just Purity
We conduct an array of tests via HPLC and other methods for our peptides:
purity, weight, endotoxins(LPS), sterility (bacteria & yeast), and TFA content.
Transparency. Trusted. Reliable.
- Batch number on every vial
- Published Certificates of Analysis
- Expert customer service
- Satisfaction and quality guarantee
- Cold pack styrofoam shipping
- Secure credit card payment
Explore Other High-Purity Peptides
Peptides
Blend: BPC-157 TB-500 Peptide (20MG)
$107.00
$107.00
Peptides
GHK-Cu Copper Peptide 100MG
$49.99
Peptides
Ipamorelin Peptide (10MG)
$53.00
Peptides
CJC-1295 DAC Peptide (5MG)
$41.99
Peptides
AOD-9604 Peptide (10MG)
Original price was: $84.99.$68.00Current price is: $68.00.
Peptides
BPC-157 Peptide (10MG)
$53.00
Peptides
TB-500 Peptide (TB4) 10MG
$62.00
Peptides
NAD+ Peptide (1000MG)
$119.00
What is CJC-1295?
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog designed for prolonged biological activity. Unlike traditional short-acting GHRH peptides, CJC-1295 covalently binds to endogenous albumin, forming a drug-affinity complex (DAC) that extends its half-life to match that of albumin. This albumin binding mechanism allows sustained GHRH receptor activation and prolonged GH release. As a long-acting GHRH analog, CJC-1295 represents a new generation designed to overcome rapid enzymatic degradation and short systemic residence time observed in earlier peptides.
CJC-1295 Research Studies
Peer-reviewed scientific research findings
📚 Peer-Reviewed Study
Published Study: Daily CJC-1295 Administration Normalizes Growth in Knockout Mouse
Study Background and Objective
Growth hormone–releasing hormone (GHRH) deficiency causes proportionate dwarfism and pituitary hypoplasia due to reduced somatotroph proliferation. While recombinant GH therapy remains the primary treatment for GH deficiency, it does not replicate natural pulsatile GH secretion. Conventional GHRH animal research showed limitations by its short plasma half-life, requiring multiple daily injections or continuous infusion. Previous GHRH analogs failed to normalize growth even with twice-daily dosing.
The present study addressed these challenges by testing a long-acting GHRH analog, CJC-1295, to evaluate whether it could normalize growth and body composition in GHRH knockout (GHRHKO) mice, and to determine the minimal effective dosing interval.
What Is CJC-1295?
CJC-1295 is a synthetic GHRH analog designed for prolonged biological activity. Unlike traditional short-acting GHRH peptides, CJC-1295 covalently binds to endogenous albumin, forming a drug-affinity complex (DAC) that extends its half-life to match that of albumin. This albumin binding mechanism allows sustained GHRH receptor activation and prolonged GH release.
As a long-acting GHRH analog, CJC-1295 represents a new generation of growth hormone–releasing hormone (GHRH) analogs designed to overcome rapid enzymatic degradation and short systemic residence time observed in earlier peptides. Previous CJC-1295 studies in animals showed prolonged elevations in serum GH and IGF-1 after administration, validating its pharmacological design.
Experimental Design
Researchers used male GHRH knockout (GHRHKO) mice, which lack endogenous GHRH production, and heterozygous (HTZ) littermates as normal controls.
Groups and dosing:
- CJC-1295 administered subcutaneously at 2 µg every 24 h, 48 h, or 72 h for 5 weeks.
- Placebo groups: GHRHKO + vehicle and HTZ + vehicle.
- Body metrics: weight, naso-anal length, femur and tibia lengths.
- Body composition: lean mass, visceral fat, and subcutaneous fat percentages.
- Pituitary assessment: total RNA yield, GH and prolactin mRNA via Northern blot, GH protein via Western blot, and immunohistochemistry for somatotroph proliferation.
- Serum IGF-1: determined at study termination to evaluate systemic anabolic effects.
Key Findings of the CJC1295 Study
Growth normalization:
Daily CJC-1295 (24 h dosing) fully normalized body weight, naso-anal length, and femur/tibia lengths—matching normal HTZ mice.
Partial improvements with reduced frequency:
48 h dosing produced intermediate effects with normal bone length but submaximal total growth. 72 h dosing improved growth compared to placebo but did not achieve full normalization.
Pituitary and RNA data:
Total pituitary RNA increased 13-fold, 9-fold, and 7-fold in 24 h, 48 h, and 72 h groups, respectively. GH mRNA rose proportionally (11-, 8-, and 6-fold increases) and was supported by higher GH protein expression.
Cellular effects:
Immunohistochemistry confirmed significant somatotroph cell proliferation, while prolactin cell changes were minimal.
Serum IGF-1:
Only daily administration significantly elevated circulating IGF-1 levels. Less frequent dosing showed no statistical increase, correlating with diminished growth response.
Study Results of Dosing Frequency in Mice
Implications for Research and CJC1295 Peptide Studies
This study provides pivotal evidence for optimizing CJC-1295 routes of administration in experimental models. It demonstrates that administration frequency strongly influences growth outcomes, confirming that daily dosing maintains physiological GH and IGF-1 signaling.
The findings advance the understanding of CJC-1295 studies by establishing the relationship between injection interval, peptide bioavailability, and biological response. Moreover, the albumin-binding DAC design underscores how structural modifications can enhance peptide stability and extend systemic exposure—principles applicable to future GHRH analog development and dosing research.
Conclusion
Once-daily administration of CJC-1295 successfully normalized growth and body composition in GHRHKO mice by restoring pituitary GH production and elevating IGF-1 levels. Dosing every 48 h or 72 h yielded partial results, emphasizing that administration frequency determines therapeutic success.
The study highlights the translational potential of long-acting GHRH analogs in peptide research and supports future investigations into dose optimization and pharmacokinetics across species. Proper dosing intervals are essential for maintaining consistent biological activity and mimicking physiological GH release patterns.
Frequently Asked Questions (FAQ)
What does CJC-1295 do in research studies?
CJC-1295 acts as a growth hormone–releasing hormone (GHRH) analog that stimulates GH secretion and somatotroph proliferation, supporting growth and anabolic activity in experimental models.
How is CJC-1295 administered in experimental models?
It is typically administered subcutaneously in controlled intervals—daily, every 48 h, or every 72 h—depending on the research objective. This study identified daily injections as the most effective route.
What makes CJC-1295 different from traditional GHRH?
Its albumin-binding mechanism greatly extends peptide half-life, allowing prolonged GH stimulation compared with short-acting natural GHRH.
Can CJC-1295 normalize growth in knockout models?
Yes. Daily dosing restored normal body weight, skeletal growth, and pituitary function in GHRH-deficient mice.
Why was daily CJC-1295 more effective than 48h or 72h dosing?
Because mice have a shorter albumin half-life (~24 h), less frequent dosing led to insufficient peptide levels, reducing bioactivity between injections.
How does albumin binding extend peptide half-life?
CJC-1295 forms a covalent bond with albumin, which circulates for days, preventing rapid enzymatic degradation and renal clearance.
What does this study reveal about optimizing GHRH analog research?
It shows that both molecular design and dosing schedule critically influence outcomes, offering a model for refining peptide-based endocrine research.
Study Reference
Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
https://pubmed.ncbi.nlm.nih.gov/16822960/
Hear What Our Customers Say
Trusted by thousands of researchers for high-quality peptides
This is a first class operation. Quality products and the best customer service. There may be many similar type of companies out there, but this one is trusted and affordable. No price gouging! I highly recommend this company!
Verified Peptides is hands down my favorite website for these products. I can always count on the products to be legitimate and effective, all while being affordable. Will continue to give them my business.
Outstanding product, outstanding price, outstanding shipping